Challenges in Translational Nanomedicine

S.M. Moghimi
University of Copenhagen, DK

Keywords: nanomedicine, nanotoxicology, personalized nanomedicine


Nanomedicine encompasses enabling technologies to achieve and facilitate earlier and more precise disease diagnosis, effective targeted therapies (eliminating side effects), better therapy and monitoring. Furthermore, the nanomedicine umbrella is considered the enabling instrument for personalized, targeted and regenerative medicine that can deal with grand challenges of chronic diseases in an aging population. This may enhance the quality of life, support a healthier more independent aging population and instrumental for cost-effective health care. A long-term goal is ‘personalization’ of nanomedicine and theranostics; but can nanomedicine be personalized for prognosis, diagnosis and drug treatment? At large, and from a high risk−high gain perspective, this requires a heroic integration of multifaceted health nanotechnology platforms with genomics and epigenomics knowledge together with complex computational approaches and bioinformatics. But how and where do we start? Which diseases do we focus? Which markets should we consider? What business models should we apply? Immunological reactions to man-made nanomaterials and nanomedicines are particularly notable. Provisions in innate immunity gene profiling for nanomedicine risk assessment and safety may serve a good starting point, and forms the centre of this discussion.